MDB Capital Holdings Provides Third Quarter 2026 Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MDB Capital Holdings (NASDAQ: MDBH) reported higher fee income while advancing four businesses toward financing, commercialization and clinical milestones. Fee income rose 96% to $4.2 million for the nine months ended September 30, 2026, from $2.1 million a year earlier. Cash and cash equivalents totaled $8.3 million at September 30; operating expenses were flat against both the prior year and prior quarter.
Public Ventures is discussing partnerships and a potential independent launch. PatentVest is seeking financing ahead of planned independence in 2027. eXoZymes selected Curia for commercial-scale manufacturing support. Paulex Bio registered a first-in-human Phase 1/2a trial of PAL-119. MDB is pursuing cost reductions and external funding to minimize dilution, while its board reviews structures for sharing any realized business value with shareholders.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFee income rose 96% to $4.2 million for nine months ended September 30, 2026, versus $2.1 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.PatentVest plans independence in 2027, while pursuing financing to expand its client base and marketing.
- Moderate pointMDB is working to reduce operating costs and pursuing external funding and partnerships to minimize shareholder dilution.
- Minor pointeXoZymes selected Curia as its first commercial-scale manufacturing partner to support NCT technology transfer and scale-up.
- Minor pointPaulex Bio registered a first-in-human Phase 1/2a trial of investigational oral diabetes candidate PAL-119.
- Minor pointMDB’s board is reviewing structures for sharing any value realized from its businesses with shareholders.
Negative
- Moderate pointPublic Ventures partnerships remain in discussions, including a potential launch independent of MDB.
- Minor pointPatentVest’s growth financing remains in pursuit ahead of its planned independence.
Key Figures
- Nine-month fee income
- 96% increase to $4.2 million
- Nine months ended September 30, 2026; $2.1 million a year earlier
- Cash and cash equivalents
- $8.3 million
- As of September 30, 2026
- Trial stage
- Phase 1/2a
- PAL-119 first-in-human trial; registration announced
Key Terms
first-in-human medical
beta cell medical
technology transfer technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to Host Zoom Webinar Today at 4:30 p.m. ET
Addison, TX, Nov. 17, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching early-stage technology companies, today provides a business update for the quarter ended September 30, 2026, and subsequent developments. MDB is focusing its resources on advancing Public Ventures, PatentVest, eXoZymes and Paulex Bio toward their next milestones while working to reduce operating costs and continuing to pursue select new public venture opportunities.
Business and Strategic Highlights
- MDB focused on moving four validated Big Ideas toward a value inflection point:
- Public Ventures. MDB is in discussions with potential strategic and capital partners to expand the reach of Public Ventures’ self-clearing platform, including a potential launch independent of MDB.
- PatentVest. Our innovative IP law firm is pursuing financing to grow its client base at scale and expand its marketing efforts in preparation to become an independent company in 2027.
- eXoZymes (Nasdaq: EXOZ). eXoZymes selected Curia as its first commercial-scale manufacturing partner to support technology transfer and scale-up of NCT as it advances toward commercial manufacturing along with announcing new compounds with large market potential.
- Paulex Bio. Paulex announced the registration of a first-in-human Phase 1/2a trial of PAL-119, an investigational oral drug candidate targeting the root cause of Type 1 and Type 2 diabetes. The study is designed to evaluate safety and tolerability and explore beta cell expansion.
- MDB’s objective is to realize value from these businesses for shareholders as they reach key milestones. The Board is reviewing potential structures for sharing any value realized with shareholders.
Financial Highlights
- Fee income increased
96% to$4.2 million for nine months ended September 30, 2026, from$2.1 million a year earlier. - Cash and cash equivalents totaled
$8.3 million as of September 30, 2026. - Total operating expenses were flat compared to both the prior year and the prior quarter.
- MDB is pursuing external funding and partnerships for Public Ventures and PatentVest and working to reduce operating costs, with the goal of minimizing any dilution to shareholders.
Third Quarter 2026 Update Zoom Webinar at 4:30 p.m. ET Today
Christopher Marlett, CEO and co-founder of MDB will lead the webinar to review recent developments and ongoing initiatives as well as host a question-and-answer session.
Investors can register for the Zoom webinar HERE. The live webinar can also be accessed on through MDB’s investor relations website.
About MDB Capital Holdings, LLC
Founded in 1997, MDB Capital focuses on launching "Big Ideas" through a unique approach to public venture capital. The firm emphasizes community-driven financings of early-stage leaders in significant business and technology categories via early public offerings, primarily on NASDAQ, as well as post-IPO offerings for qualifying companies. MDB Capital Holdings, LLC (NASDAQ: MDBH) and its subsidiaries operate under the MDB Capital brand, including Public Ventures, LLC (d/b/a MDB Capital), a venture-focused broker-dealer that operates the MDB Direct trading platform, and PatentVest, Inc., an intellectual property law firm. MDB Capital, a d/b/a of Public Ventures, LLC, is a registered broker-dealer and Member FINRA/SIPC. For more information, visit www.mdb.com.
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond MDB's control. MDB's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in documents that may be filed by MDB from time to time with the SEC. The forward-looking statements included in this press release represent MDB's views as of the date of this press release. MDB anticipates that subsequent events and developments will cause its views to change. MDB undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing MDB's views as of any date subsequent to the date of this press release.
Investor Relations Contact:
IR@mdb.com
Media Contact:
press@mdb.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did MDB Capital Holdings’ fee income increase in its third-quarter 2026 update?
MDB’s fee income increased 96% to $4.2 million for the nine months ended September 30, 2026, from $2.1 million a year earlier. These figures cover the nine-month period, not the third quarter alone.
What will Paulex Bio’s PAL-119 trial evaluate?
The registered first-in-human Phase 1/2a trial is designed to evaluate safety and tolerability and explore beta cell expansion. PAL-119 is an investigational oral drug candidate that Paulex describes as targeting the root cause of Type 1 and Type 2 diabetes.